Mizuho Begins Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Equities researchers at Mizuho initiated coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report released on Friday, MarketBeat reports. The firm set an “outperform” rating and a $8.00 price target on the stock. Mizuho’s target price indicates a potential upside of 56.56% from the company’s current price.

ZNTL has been the subject of a number of other reports. Guggenheim lifted their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $6.14.

Zentalis Pharmaceuticals Stock Up 11.8%

Shares of ZNTL stock opened at $5.11 on Friday. Zentalis Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $6.95. The firm has a market cap of $363.78 million, a price-to-earnings ratio of -2.95 and a beta of 1.92. The stock has a 50-day moving average price of $4.10 and a 200 day moving average price of $3.35.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Sell-side analysts predict that Zentalis Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Sivia Capital Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $27,000. CTC Alternative Strategies Ltd. acquired a new position in Zentalis Pharmaceuticals during the first quarter valued at approximately $29,000. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals during the second quarter valued at approximately $37,000. Voleon Capital Management LP bought a new stake in Zentalis Pharmaceuticals during the third quarter worth $41,000. Finally, State of Wyoming bought a new stake in Zentalis Pharmaceuticals during the first quarter worth $67,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.